59917-39-4

Basic information

• Product Name: Vindesine sulfate
• Synonyms: Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-, sulfate (1:1) (salt);VINDESINE SULFATE SALT;Fildesi;LY-099094;VINCRISITINESULFATE;Desacetylvinblastine amide sulfate salt;Methyl (1S,13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbaMoyl-12-ethyl-10,11-dihydroxy-5-Methoxy-8-Methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0^{4,12}.;Elsedine
• CAS NO: 59917-39-4
• Molecular Formula: C₄₃H₅₅N₅O₇*H₂O₄S
• Molecular Weight: 852
• EINECS: 261-984-7
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Anti-cancer & immunity
• Mol File: 59917-39-4.mol
• Article Data: 0

Chemical Properties

• Melting Point: >2500C
• Appearance: off-white to light yellow/
• Density: 1.41 g/cm3
• Storage Temp.: 2-8°C
• Solubility: deionized water: ≥50mg/mL
• Stability: Hygroscopic
• CAS DataBase Reference: Vindesine sulfate(CAS DataBase Reference)
• NIST Chemistry Reference: Vindesine sulfate(59917-39-4)
• EPA Substance Registry System: Vindesine sulfate(59917-39-4)

Safety Data

• Hazard Codes: Xn
• Statements: 40
• Safety Statements: 26-36
• RIDADR: 1544
• WGK Germany: 3
• RTECS: YY8090000
• HazardClass: 6.1(a)
• PackingGroup: II
• Hazardous Substances Data: 59917-39-4(Hazardous Substances Data)

Usage

Description

Vindesine sulfate is a synthetic derivative of the dimeric Catharanthus alkaloid vinblastine, which is an antineoplastic agent. It is a pharmaceutical compound with significant potential in the treatment of various types of cancer.
Used in Oncology:
Vindesine sulfate is used as an antineoplastic agent for its anticancer properties. It is particularly effective in the treatment of various malignancies due to its ability to inhibit the growth and spread of cancer cells.
Used in Pharmaceutical Industry:
Vindesine sulfate is used as a key component in the development of cancer therapeutics. Its antineoplastic properties make it a valuable asset in the creation of medications aimed at combating cancer and improving patient outcomes.

InChI:InChI=1/C43H55N5O7.H2O4S/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50;1-5(2,3)4/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50);(H2,1,2,3,4)/t25-,34+,35-,36-,39+,40-,41-,42+,43+;/m1./s1